May 30, 2018
A Massachusetts federal judge on Wednesday granted final approval to an $18 million settlement Aveo Pharmaceuticals Inc. reached with investors to close a five-year-old class action stock-drop case that was dismissed twice before it was certified.
May 10, 2018
New York-based law firm Pomerantz LLP and Boston firm Shapiro Haber & Urmy LLP asked a Massachusetts federal judge late Wednesday to approve a $5 million fee request after representing investors in a twice-dismissed stock drop suit against Aveo Pharmaceuticals Inc. that ended in an $18 million deal.
February 02, 2018
Investors in Aveo Pharmaceuticals Inc. on Friday asked a Massachusetts federal judge for an initial sign-off on a deal worth more than $17.7 million that would resolve a class action alleging the drugmaker hid U.S. Food and Drug Administration concerns about tivozanib, Aveo's drug candidate for treating kidney cancer.
November 15, 2017
A Massachusetts federal judge on Tuesday granted class certification to a group of investors claiming Aveo Pharmaceuticals Inc. misled them about concerns the U.S. Food and Drug Administration had about the company's kidney cancer drug.
June 29, 2017
Investors claiming Aveo Pharmaceuticals Inc. hid U.S. Food and Drug Administration concerns about its kidney cancer drug from them asked a Massachusetts federal court Thursday to certify their proposed class, calling it a "textbook example" of a securities case warranting class action treatment.
March 20, 2015
A Massachusetts federal judge on Friday dismissed a proposed shareholder class action accusing Aveo Pharmaceuticals Inc. of deceiving investors about the riskiness of its kidney cancer drug, finding the investors have failed to show the drugmaker's management knowingly defrauded them.
May 10, 2013
Aveo Pharmaceuticals Inc. was hit with a proposed class action Thursday accusing it of hiding that the U.S. Food and Drug Administration found that its kidney cancer treatment drug Tivozanib increased patients' risk of death more than competitors and that Aveo's trials for the drug were inadequate.